platoseedplatoseed
Multimodal AI Platform for Modality Agnostic Drug Discovery™
We are the only AI-native biotech pioneering small and large molecule therapeutics discovery by integrating massive multimodal data, frontier AI models, and high-throughput lab automation into an infrastructure for AI-enabled drug discovery.
1910 is an AI-native biotech company offering a multimodal, modality-agnostic platform for drug discovery that combines large-scale multimodal data, frontier AI models, and high-throughput lab automation to enable AI-enabled therapeutics discovery and development.
Their ITO Platform and PEGASUS/CANDID-CNS capabilities integrate multimodal data and AI models with automated lab workflows to enable small and large molecule discovery. The platform supports co-engineering at data, AI models, and compute layers, providing interactive tools such as dashboards and chatbots to tailor discovery modules for an organization.
Who it’s for: Biotech and pharmaceutical companies seeking AI-enabled, multimodal drug discovery capabilities and bespoke molecule-design tooling.
publications and news mentions; product/platform launches; collaboration and partnership inquiries
AI platform accelerating therapies for rare & inflammatory diseases.
Arpeggio Bio develops drugs targeting transcription factors using AI…
